CRISPR Therapeutics AG (CRSP)
55.65
-0.76
(-1.35%)
USD |
NASDAQ |
Apr 24, 16:00
55.93
+0.28
(+0.50%)
After-Hours: 20:00
CRISPR Therapeutics Revenue (TTM)
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| June 30, 2023 | 170.10M |
| March 31, 2023 | 100.26M |
| December 31, 2022 | 0.436M |
| September 30, 2022 | 12.78M |
| June 30, 2022 | 13.01M |
| March 31, 2022 | 913.06M |
| December 31, 2021 | 913.08M |
| September 30, 2021 | 900.93M |
| June 30, 2021 | 900.75M |
| March 31, 2021 | 0.588M |
| December 31, 2020 | 0.543M |
| September 30, 2020 | 77.36M |
| June 30, 2020 | 289.14M |
| March 31, 2020 | 289.42M |
| Date | Value |
|---|---|
| December 31, 2019 | 289.59M |
| September 30, 2019 | 212.69M |
| June 30, 2019 | 1.324M |
| March 31, 2019 | 2.094M |
| December 31, 2018 | 3.124M |
| September 30, 2018 | 35.33M |
| June 30, 2018 | 37.16M |
| March 31, 2018 | 39.65M |
| December 31, 2017 | 41.00M |
| September 30, 2017 | 11.02M |
| June 30, 2017 | 10.18M |
| March 31, 2017 | 7.391M |
| December 31, 2016 | 5.164M |
| September 30, 2016 | 3.067M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
0.436M
Minimum
Dec 2022
913.08M
Maximum
Dec 2021
299.12M
Average
170.10M
Median
Jun 2023
Revenue (TTM) Benchmarks
| Vertex Pharmaceuticals Inc | 9.869B |
| Intellia Therapeutics Inc | 36.28M |
| Novartis AG | 51.01B |
| Verve Therapeutics Inc | 11.76M |
| AC Immune SA | -- |